FFA
ENGN icon

Farther Finance Advisors’s enGene Therapeutics ENGN Stock Holding History

Farther Finance Advisors’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$173 Buy
+100
New +$408 ﹤0.01% 5739

Other funds holding ENGN

MAM
Marquette Asset Management Minneapolis, Minnesota $779M AUM 23.4% 1-Year Est. Return
PP
PFS Partners Mine Hill, New Jersey $247M AUM 29.02% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Farther Finance Advisors's ENGN Position: Q2 2026 in Review

Farther Finance Advisors opened a new position in enGene Therapeutics (ENGN) in Q2 2026: 100 shares worth $173. The stake represents ﹤0.01% of the portfolio and ranks #5739 among its holdings.

4 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • Farther Finance Advisors held 100 shares of enGene Therapeutics worth $173 as of Q2 2026.
  • enGene Therapeutics was a new Farther Finance Advisors position in Q2 2026.
  • enGene Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #5739 holding.
  • 4 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.